Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02141451 · ClinicalTrials.gov registry record · Phase 1
ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL
A Phase 1 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT02141451 is a Phase 1 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 30 participants.
The verdict
NCT02141451, a Phase 1 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a single institution phase I/II study using an ADAM17 inhibitor (INCB7839) with rituximab as consolidation therapy after an autologous hematopoietic cell transplant (HCT) for patients with diffuse large B cell lymphoma (DLBCL). The study consists of two phases. The dose finding phase is a modified version of a phase I trial and the extended phase is a modified version of a phase II trial.
Interventions
- DRUG Rituximab
- DRUG INCB7839
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2014-05 |
| Est. Completion | 2019-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02141451
The ClinicalTrials.gov registry entry for NCT02141451 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT02141451 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02141451 about?
NCT02141451 is a clinical study titled "ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCL". This is a single institution phase I/II study using an ADAM17 inhibitor (INCB7839) with rituximab as consolidation therapy after an autologous hematopoietic cell transplant (HCT) for patients with diffuse large B cell lymphoma (DLBCL). The study consists of two phases. The dose finding phase is a mo...
What is the current status of trial NCT02141451?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2014-05. Estimated completion is 2019-06.
What interventions are being tested in trial NCT02141451?
The interventions under investigation include: Rituximab (DRUG), INCB7839 (DRUG).
Who is sponsoring clinical trial NCT02141451?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.